United Therapeutics Profit Falls 24% To $258.6 Million As R&D Expense Jumps 119%

Revenue rose 4% to $832.5 million, but a Thymmune-related research cost and a higher tax rate cut earnings, and the board approved a $2.0 billion buyback.

Share
United Therapeutics Profit Falls 24% To $258.6 Million As R&D Expense Jumps 119%

United Therapeutics, which develops drugs for pulmonary arterial hypertension, said third-quarter net income fell 24% to $258.6 million even as revenue rose 4% to $832.5 million, according to an 8-K filed Wednesday. A jump in research spending tied partly to its Thymmune Therapeutics acquisition outweighed a $66.5 million reversal of a Sandoz litigation accrual.

Tyvaso DPI grows, nebulized Tyvaso slips

Revenue compared with $799.5 million a year earlier. Diluted earnings per share were $5.71, against $7.16.

Tyvaso DPI sales climbed 13% to $378.5 million, while nebulized Tyvaso fell 12% to $125.3 million. Total Tyvaso rose 5% to $503.8 million. Orenitram rose 11% to $145.0 million, and Remodulin slid 3% to $122.0 million.

The company said it believes the availability of competitive therapies hurt sales of nebulized Tyvaso, Tyvaso DPI and Remodulin.

The company also sells Unituxin, a treatment for a rare childhood cancer, which rose 9% to $52.3 million. Adcirca fell 54% to $4.5 million.

Research costs and a higher tax bill

Research and development expense rose 119% to $279.2 million. Its "Other" category reached $130.0 million, up from $4.8 million; that category covers costs to acquire in-process research assets, upfront and milestone payments under license deals, and fair-value adjustments to contingent consideration. The company said the overall increase was primarily due to higher in-process research expense from the Thymmune acquisition, which it accounted for as an asset acquisition, along with spending on manufactured organ projects and cardiopulmonary treatments.

The effective tax rate rose to 31% from 23%, which the company attributed primarily to the nondeductible Thymmune research expense. Income tax expense was $114.2 million, up from $99.3 million.

Selling, general and administrative expense fell 20% to $146.4 million because of the Sandoz reversal. The company agreed in October to settle that matter in connection with its settlement with Liquidia Technologies, and the Sandoz case was dismissed on October 28. Operating income was $307.8 million, down from $388.5 million.

Buybacks and a $3.5 billion cash pile

The board approved a new repurchase program of up to $2.0 billion in October, running through October 21, 2027. The March program of the same size is fully used, with a September accelerated repurchase deal with Citibank taking the final $477.6 million.

The company expects final settlement of that September agreement in the fourth quarter. In the third quarter it repurchased 980,394 shares in total. Cash, cash equivalents and marketable investments stood at $3,535.7 million on September 30. Interest income fell to $33.7 million from $46.4 million, as securities were sold to fund the buybacks.

Chief Executive Martine Rothblatt said the company is "entering a period of extraordinary growth."

Sources

More on United Therapeutics

All United Therapeutics (UTHR) coverage →